Back to Search Start Over

Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration

Authors :
Chatzidionysiou, Katerina
Lie, Elisabeth
Nasonov, Evgeny
Lukina, Galina
Hetland, Merete Lund
Tarp, Ulrik
van Riel, Piet L C M
Nordström, Dan C
Gomez-Reino, Juan
Pavelka, Karel
Tomsic, Matija
Kvien, Tore K
van Vollenhoven, Ronald F
Gabay, Cem
Chatzidionysiou, Katerina
Lie, Elisabeth
Nasonov, Evgeny
Lukina, Galina
Hetland, Merete Lund
Tarp, Ulrik
van Riel, Piet L C M
Nordström, Dan C
Gomez-Reino, Juan
Pavelka, Karel
Tomsic, Matija
Kvien, Tore K
van Vollenhoven, Ronald F
Gabay, Cem
Source :
Chatzidionysiou , K , Lie , E , Nasonov , E , Lukina , G , Hetland , M L , Tarp , U , van Riel , P L C M , Nordström , D C , Gomez-Reino , J , Pavelka , K , Tomsic , M , Kvien , T K , van Vollenhoven , R F & Gabay , C 2012 , ' Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration ' , Annals of the Rheumatic Diseases , vol. 71 , no. 3 , pp. 374-377 .
Publication Year :
2012

Abstract

OBJECTIVES: To compare the effectiveness and safety of rituximab alone or in combination with either methotrexate or leflunomide.METHODS: 10 European registries submitted anonymised datasets with baseline, 3, 6, 9 and 12-month clinical data from patients who started rituximab.RESULTS: 1195 patients were treated with rituximab plus methotrexate, 177 with rituximab plus leflunomide and 505 with rituximab alone. Significantly more patients achieved a European League Against Rheumatism good response at 6 months when treated with rituximab plus leflunomide (29.1%) compared with rituximab plus methotrexate (21.1%) and rituximab alone (19.3%; p=0.02 and p=0.01, respectively). Similar results were observed at 12 months. Adverse events occurred in 10.2%, 13.2% and 13.9% of patients on rituximab plus leflunomide, rituximab plus methotrexate and rituximab alone, respectively.CONCLUSIONS: Leflunomide is an effective and safe alternative to methotrexate as concomitant treatment with rituximab. Slightly better results were obtained by the combination of rituximab and leflunomide than rituximab and methotrexate, raising the possibility of a synergistic effect of leflunomide and rituximab.

Details

Database :
OAIster
Journal :
Chatzidionysiou , K , Lie , E , Nasonov , E , Lukina , G , Hetland , M L , Tarp , U , van Riel , P L C M , Nordström , D C , Gomez-Reino , J , Pavelka , K , Tomsic , M , Kvien , T K , van Vollenhoven , R F & Gabay , C 2012 , ' Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration ' , Annals of the Rheumatic Diseases , vol. 71 , no. 3 , pp. 374-377 .
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1322619635
Document Type :
Electronic Resource